

**CASE REPORT**

**DRESS Syndrome- Uncommon Drug Reaction with Common Disease  
Treatment: A Case Report**

B Saroj Kumar Prusty<sup>1</sup>, Majed Abdulbasit Momin<sup>2</sup>, Yugvaveer K Goud<sup>3</sup>, Kiran Kumar Ramineni<sup>4</sup>, Safina Perveen<sup>1</sup>

<sup>1</sup>*Yashoda Hospitals, Malakpet Branch Hyderabad, Department of Critical Medicine, Hyderabad, India*

<sup>2</sup>*Yashoda Hospitals, Malakpet Branch Hyderabad, Department of Laboratory Medicine, Hyderabad, India*

<sup>3</sup>*Yashoda Hospitals, Malakpet Branch Hyderabad, Department of Pulmonology, Hyderabad, India*

<sup>4</sup>*Yashoda Hospitals, Malakpet Branch Hyderabad, Department of Neurology, Hyderabad, India*

**ABSTRACT**

Drug Reaction with Eosinophilia and Systemic symptoms (DRESS syndrome), is a severe adverse reaction associated with diverse collection of drugs, characterized by severe mucocutaneous rash, eosinophilia, fever, lymphadenopathy and extensive systemic involvement. We report a case of a 21-year-old female who developed clinical manifestations of fever, maculopapular rash, lymphadenopathy, eosinophilia and systemic symptoms after taking antitubercular medication for pulmonary tuberculosis, with subsequent development of acute liver failure with encephalopathy and coagulopathy. She was managed successfully with withdrawal of the offending medication and supportive care in intensive care unit. This case highlights the importance of consideration of antitubercular medication related drug reaction even with delayed onset of symptoms. *J Microbiol Infect Dis 2020; 10(4): 225-229.*

**Keywords:** *Anti-tubercular treatment, DRESS syndrome, Eosinophilia, Management*

**INTRODUCTION**

Drug Reaction with Eosinophilia and Systemic symptoms (DRESS) syndrome is a rare, delayed cutaneous hypersensitivity reaction, seen more commonly with anticonvulsants, sulfonamides, anti-depressants, anti-inflammatory agents, antivirals, ACE inhibitors and Beta blockers etc. [1]. Although tuberculosis is a common infectious disease in developing countries, like India, drug reaction with Antitubercular therapy (ATT) has not been routinely reported as the causative agent for DRESS syndrome.

This syndrome causes a diverse array of clinical symptoms, usually two to eight weeks after initiating the offending drug. The clinical triad of DRESS syndrome consists of fever, skin rash and internal organ involvement. Delayed onset of these symptoms is an important feature of DRESS syndrome and clinical outcome also takes a long time after withdrawal of the culprit drug [2]. It is difficult to diagnose, as many of its clinical features mimic those found with other serious systemic disorders. However, early recognition of the syndrome with cessation of

the causative drug is essential in improving the outcome of this potentially fatal condition.

**CASE REPORT**

A 21-year-old female was brought to the emergency department with complaints of fever, vomiting, rash for 10 days and facial puffiness yellowish discoloration of eyes for seven days. Fever was of high grade, intermittent and associated with chills. Erythematous maculopapular rash was present all over the body including face and was associated with itching. She later developed facial puffiness and noticed yellowish discoloration of both eyes. She was diagnosed with pulmonary tuberculosis 6 weeks back and was started on Anti Tubercular drugs (Ethambutol 800 mg, Isoniazid 300 mg, Pyrazinamide 1500 mg and Rifampicin 450 mg).

General examination revealed icterus, facial puffiness and erythematous, morbilliform and pruritic rash over face, arms, trunk and legs with intact mucous membranes.

**Correspondence:** Dr. Majed Abdulbasit Momin, Yashoda Hospitals, Malakpet Branch Hyderabad, Department of Laboratory Medicine, Hyderabad, India

Email: majedmomin9@gmail.com

Received: 03 September 2019 Accepted: 25 July 2020

Copyright © JMID / Journal of Microbiology and Infectious Diseases 2020, All rights reserved



Figure 1. Diffuse Erythematous morbilliform, and exfoliative rashes all over the body including face, legs, upper limbs and chest.

Three posterior auricular lymph nodes were palpable on right side, which were of around 2cm size, discrete and soft in consistency. Abdominal palpation revealed right hypochondrial tenderness and mild splenomegaly. Ultrasonography of abdomen and pelvis showed hepatomegaly (174 mm), splenomegaly (141 mm), gallbladder wall edema and minimal free fluid in the right pleural cavity.

The lab investigation showed raised bilirubin, SGOT, and SGPT (features of acute hepatitis), prolonged PT/INR, APTT (coagulopathy), and leukocytosis with significant peripheral eosinophilia. Based on the typical clinical picture with supportive laboratory parameters a provisional diagnosis of DRESS Syndrome was made. Serial Laboratory results were abnormal as mentioned in the (Table1)

Ultrasound guided FNAC of cervical lymph node was suggestive of reactive lymphadenitis. Serology work up for other infective etiologies was negative including HIV 1 & 2, Hepatitis A, B, C& E, Dengue and EBV. Influenza Screening including H1N1 was negative.

She was admitted in intensive care unit and anti-tubercular drugs were stopped. Within 48 hours of admission patient landed in acute liver failure with worsening of coagulopathy and hepatic

encephalopathy of grade 2. She had recurrent hypoglycemic episodes secondary to acute liver failure. In addition to supportive care she was managed with injection N-Acetyl Cystein IV 100 mg/kg/ day as intravenous infusion for seven days, injection vitamin K 10 mg intravenous once daily for initial 5 days, intravenous hydrocortisone 100mg thrice daily for one week followed by oral prednisolone 1mg/kg for two weeks which was gradually tapered over next six weeks till complete resolution of eosinophilia and skin rashes. As she had worsening liver enzymes and encephalopathy on day 5, plasmapheresis was started with 3000ml of fresh frozen plasma for consecutive three days. Patient's general condition, neurological status, skin rash and laboratory parameters including Absolute eosinophilic count, liver enzymes, and PT with INR improved significantly with plasmapheresis and other supportive measures. She was successfully discharged on day 27 in a stable condition. Modified ATT including Levofloxacin 750 mg once daily, Amikacin 1gm IV once daily and Ethambutol 800mg once daily were initiated. On follow up at 6 weeks, 8 weeks and 12 weeks she maintained clinical and laboratory parameter improvement and was independent for activities of daily living. So modified ATT as prescribed above was continued for 2 months and amikacin was stopped. Isoniazid and cycloserine were added sequentially without any adverse effects.

## DISCUSSION

The term DRESS syndrome was first coined by Bocquet et al in 1996. As per Bocquet's criteria the diagnosis of DRESS syndrome requires the following 3 features: 1) skin eruption, 2) blood eosinophilia ( $>1.5 \times 10^3/\mu\text{L}$ ) or the presence of atypical lymphocytes, and 3) internal organ involvement, including lymphadenopathies ( $>2$  cm in diameter), hepatitis (liver transaminases values  $>$  twice the upper normal limit), interstitial nephritis, and interstitial pneumonia or carditis [3]. Fever and rash are the common initial symptoms. Rash is usually macular, appears first on the face, abdomen and upper limbs. Lymphadenopathy is seen in 75% cases and liver is the most commonly affected internal organ.

Table-1. Laboratory parameters of the patient.

Variables	Day 1	Day 3	Day 5	Day 10	Day 15	Day 20	Day 27
Hemoglobin gm%	11.6	10.5	10	7.1	8.5	8.6	9.1
TLC cells/cumm	37100	40800	28900	15400	15200	14100	13600
DC % N, L, E, M, B	3,20,22,5,0	50,25,20,5,0	52,20,24,4,0	54,26,10,6,0	59,22,11,4,0	59,20,10,6,0	59,22,9,5,0
AEC cells/cmm	8162	8160	6936	1540	1672	1410	1224
Platelets lacs/cumm	3.62	2.50	1.70	1.80	1.40	2.10	2.20
T. bilirubin mg/dl	5	7.3	10.5	9.44	10.25	16.27	5.2
SGOT U/L	450	465	547	94	85	112	53
SGPT U/L	232	330	405	170	56	55	20
ALP U/L	277	236	159	99	91	161	166
GGT U/L	123	110	56	60	69	110	182
PT secs/INR	53.1/5.86	44.3/4.67	39.5/4.05	22.7/1.95	17.5/1.41	18.9/1.55	16/1.24
aPTT secs	70	72	60.8	36.4	36.2	34.6	32.1
RBS mg/dl	92	65	72	75	70	80	100
Serum Creatinine mg/dl	0.5	0.6	0.5	0.3	0.4	0.5	0.6
Na, K, Cl (Serum) meq/L	30/4.1/99	136/3.9/99	138/3.0 /93	141/4.2/98	136/3.4/96	138/4.1/98	140/3.8/96

Table 2: Drug groups associated with DRESS syndrome.

Drug groups	Specific drug
Anticonvulsants	Phenytoin, carbamazepine, phenobarbital, lamotrigine, valproate
Anti-inflammatories	Piroxicam, naproxen, diclofenac, sulindac, ibuprofen, celecoxib
Anti-infective agents	Abacavir, telaprevir, nevirapine, linezolid, doxycycline, nitrofurantoin, vancomycin, minocycline, ampicillin, isoniazid, rifampicin
Antidepressants	Despiramine, amitriptyline, fluoxetine
Sulfonamides/sulfones	Dapsone, sulfasalazine, trimethoptim-sulfametoxazole
Angiotensin-converting enzyme inhibitors	Captopril, enalapril
Beta-blockers	Atenolol, celiprolol

In 2007, Kardaun et al [4] of severe cutaneous adverse reaction (RegiSCAR) study group published a scoring system including various parameters like skin eruption, fever (>38.5 °C), lymphadenopathy, involvement of at least 1 internal organ, blood eosinophilia (>10% or 700/μL), presence of atypical lymphocytes and negative evaluation for other potential causes. A

composite score of more than five indicates a definite case of DRESS. Our case satisfied the criteria for the definite diagnosis of DRESS syndrome.

Although exact pathogenesis is not clear, both genetic and acquired factors related to drug metabolism contribute to the susceptibility for the development of DRESS in a given individual

[5]. Various groups of drugs associated with DRESS include anticonvulsants, antibiotics, antivirals, analgesics etc. [6,7]. Details are summarized in Table 2.

DRESS syndrome usually develops within 2 months of ingestion of the offending drug. In addition to meticulous clinical examination, minimum evaluation required for diagnosis include hemogram with absolute eosinophil count, lymphocyte count, Liver function tests, serum creatinine, serum electrolytes, Electrocardiogram, Chest X ray and ultrasound abdomen. Diagnostic differentials include Stevens–Johnson syndrome (SJS), Toxic epidermal necrolysis (TEN), hyper eosinophilic syndrome and Erythroderma [6].

The management protocols are not based on any consensus or guidelines. The primary strategy is to stop the offending drug. Systemic steroid therapy should begin with a minimum dose of 1.0 mg/kg/day of prednisone or equivalent along with supportive care and close monitoring of clinical, laboratory parameters. Steroids need to be tapered slowly over 6–8 weeks, even upon clinical resolution, to prevent relapse [8]. Additional treatment options include intravenous immunoglobulins, rituximab and plasmapheresis [9].

In tuberculosis endemic countries like India, anti-tuberculosis drugs are extensively prescribed sometimes even empirically. First line drugs including Rifampicin, pyrazinamide, isoniazid and streptomycin have been reported to cause DRESS syndrome [10]. It is challenging to identify ATT drugs as potential DRESS syndrome inducers, take the risk of stopping or modifying the standard drug regimen especially with the addition of corticosteroids in the context of active infection.

Approximately 10% mortality rate is seen in DRESS syndrome, mostly due to liver damage thought to be secondary to eosinophilic infiltration. The prognosis of patients with DRESS syndrome related acute liver failure without transplantation is very poor [11].

To conclude, DRESS syndrome is an under-recognized and potentially life-threatening hypersensitivity reaction. It is an extremely uncommon complication of antitubercular medication which is commonly prescribed even

empirically in tuberculosis endemic zones like India. Coupled with meticulous clinical examination, judicious utilization of laboratory services helps in timely diagnosis, appropriate management and better outcome. Treating clinician should be vigilant and counsel the patients regarding this complication especially while prescribing the drugs associated with this syndrome.

#### ACKNOWLEDGMENTS

**Conflict of interest:** The authors declare no personal or financial conflict of interest.

**Financial Disclosure:** No financial support was received.

#### REFERENCES

1. Cacoub P, Musette P, Descamps V, et al. The DRESS syndrome: a literature review. *Am J Med* 2011; 124: 588-97.
2. Tas S, Simonart T. Drug rash with eosinophilia and systemic symptoms (DRESS syndrome). *Acta Clin Belg* 1999; 54:197-200.
3. Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). *Semin Cutan Med Surg* 1996; 15: 250-7.
4. Kardaun SH, Sidoroff A, Valeyrie-Allanore L, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? *Br J Dermatol* 2007; 156:609-11.
5. Walsh SA, Creamer D. Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking. *Clin Exp Dermatol* 2011; 36:6–11.
6. De A, Rajagopalan M, Sarda A, Das S, Biswas P. Drug reaction with eosinophilia and systemic symptoms: An update and review of recent literature. *Indian J Dermatol* 2018; 63:30-40
7. Kömür S, Ulu A, Kurtaran B, İnal AS, Taşova Y, Aksu HS. Telaprevir-related DRESS syndrome complicating hepatitis C treatment. *J Microbio Infect Dis* 2015; 5(01):36-7.
8. Sultan SJ, Sameem F, Ashraf M. Drug reaction with eosinophilia and systemic symptoms: manifestations, treatment, and outcome in 17 patients. *Int J Dermatol* 2015; 54(5):537-42.
9. Shaughnessy K, Bouchard S, Mohr M, Herre J, Salkey K. Minocycline-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome with persistent myocarditis. *J Am Acad Dermatol* 2010; 62: 315-318.

10. Palmero D, Castagnino J, Musella RM, Mosca C, González Montaner P, de Casado GC. Difficult clinical management of anti-tuberculosis DRESS syndrome. *Int J Tuberc Lung Dis* 2013; 17:76-8.

11. Ichai P, Laurent-Bellue A, Saliba F, et al. Acute liver failure/injury related to drug reaction with eosinophilia and systemic symptoms: outcomes and prognostic factors. *Transplantation* 2017; 101(8): 1830-7.